Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare(R) Pain Therapy Devices
Tuesday, June 9, 2020 1:05 PM EDT
Contract No.: 36F797-20D0118 | Contract Term: Five Years
FAIRFIELD, CT / ACCESSWIRE / June 9, 2020 / Calmare Therapeutics Incorporated, (OTC:CTTC), the pain mitigation company, was awarded a five-year, $2.5 million Federal Supply Schedule contract by the U.S. Department of Veteran Affairs for Calmare® Pain Therapy Devices.
The contract was awarded under Schedule 65 II A - Medical Equipment and Supplies under Federal Supply Schedule Solicitation RFP-797-FSS-99-0025-R9. Contract period is from June 15, 2020 through June 14, 2025.
"This is a great accomplishment for the Company," said Calmare Therapeutics President & CEO Conrad Mir. "Our team has worked diligently to reach this goal. We anticipate delivering on this contract and posting revenues in short order."
About Calmare Therapeutics, Inc.
Calmare Therapeutics, Inc. researches, develops and commercializes chronic, neuropathic pain devices. Our flagship medical device - the Calmare® Pain Therapy Device (the "Calmare Device") - is the world's only non-invasive, non-addictive modality that can successfully treat chronic, neuropathic pain. The Company holds a U.S. Food & Drug Administration 510k clearance designation on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United States and throughout the world. The Calmare Devices are commercially sold to medical practices and found in U.S. military hospitals, clinics and on installations.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
